Quick Takeaways
- RXRX - RECURSION PHARMACEUTICALS, INC. has 23 insiders with reported activity on this page.
- Net insider value flow over the last year: -$12,043,893.
- Recent transaction rows are available for direct filing-level review.
- Info
- Insider Trading
- Financials
- Holders
Insider Transactions Reported by 23 Insiders of RECURSION PHARMACEUTICALS, INC.
- Symbol
- RXRX on Nasdaq
- Location
- Salt Lake City, UT
What Changed
- Buy value: ; sell value: $12,043,892.
- Net share flow: -2,610,240.
Why This Matters
- This page gives a plain-language issuer insider context before you inspect transaction-level evidence.
- Use the filing links below to verify timestamps, codes, and ownership impacts directly from SEC forms.
Official SEC Source
Insider trading overview
Last 12 monthsNet insider flow leans to selling over the last 12 months. Net value: -$12,043,893.
Buys
$0
Shares: 0
Insiders: 0
Sells
$12,043,893
Shares: 2,610,240
Insiders: 4
Net
-$12,043,893
Shares: -2,610,240
Insiders: -4
| Window (months) | Buy shares | Sell shares | Buy $ | Sell $ | Net $ |
|---|---|---|---|---|---|
| 0-3 | 0 | 669,680 | $0 | $2,504,183 | -$2,504,183 |
| 3-6 | 0 | 885,786 | $0 | $4,038,573 | -$4,038,573 |
| 6-9 | 0 | 1,054,774 | $0 | $5,501,137 | -$5,501,137 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
RECURSION PHARMACEUTICALS, INC. executives and other stock owners filed with the SEC include:
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Lux Ventures IV, L.P. | Former 10% Owner | $137,710,376 | Mixed | 07 Dec 2021 | ||
| Mubadala Investment Co PJSC | 10%+ Owner | $137,333,970 | Mixed | 02 Mar 2023 | ||
| Zachary Bogue | Director, 10%+ Owner | $39,514,048 | Mixed | 03 Jul 2023 | ||
| Blake Borgeson | Director | $19,312,575 | -$3,525,800 | -15% | Filing P/S | 07 Apr 2026 |
| MIC Capital Partners (Public) Parallel Cayman, LP | 10%+ Owner | $14,688,335 | Mixed | 01 Nov 2021 | ||
| Dean Y. Li | Director | $13,187,001 | Mixed | 01 Apr 2026 | ||
| Michael Secora | Chief Financial Officer | $9,186,510 | Mixed | 15 Nov 2024 | ||
| Najat Khan | CEO and President, Director | $7,566,900 | -$845,425 | -10% | Filing P/S | 09 Mar 2026 |
| David Hallett | Chief Scientific Officer | $3,829,056 | Mixed | 17 Feb 2026 | ||
| Ben R. Taylor | Chief Financial Officer | $3,476,130 | -$157,704 | -4.3% | Median | 06 Apr 2026 |
| Tina Marriott | President and COO | $3,129,811 | Mixed | 15 Nov 2024 | ||
| Christopher Gibson | Director | $2,810,323 | -$7,514,964 | -73% | Filing P/S | 07 Apr 2026 |
| Shafique Virani | Chief Business Officer | $1,446,192 | Mixed | 16 Jan 2024 | ||
| David J. Mauro | Chief Medical Officer | $1,392,024 | Mixed | 15 Nov 2024 | ||
| Ramona Doyle | Chief Medical Officer | $1,280,811 | Mixed | 16 May 2022 | ||
| Zavain Dar | Director | $602,174 | Mixed | 01 Apr 2026 | ||
| Franziska Michor | Director | $565,385 | Mixed | 18 Jun 2025 | ||
| CHAVEZ R. MARTIN | Director | $529,780 | Mixed | 01 Apr 2024 | ||
| Terry-Ann Burrell | Director | $514,098 | Mixed | 01 Jul 2024 | ||
| Robert Hershberg | Director | $328,107 | Mixed | 18 Jun 2025 | ||
| Namandje Bumpus | Director | $211,628 | Mixed | 18 Jun 2025 | ||
| Elaine D. Sun | Director | $211,628 | Mixed | 18 Jun 2025 | ||
| MIC CAPITAL PARTNERS (PUBLIC) (US) IM, LLC | Other* | Mixed | 01 Nov 2021 |
Top shareholders of RECURSION PHARMACEUTICALS, INC. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| VANGUARD GROUP INC |
13F
|
Company |
9.2%
|
47,187,759
|
$192,997,934 | — | 31 Dec 2025 | |
| BlackRock, Inc. |
13F
13D/G
|
Company |
6.1%
from 13D/G
|
38,866,779
|
$158,965,127 | — | 31 Dec 2025 | |
| ARK Investment Management LLC |
13D/G
13F
|
Company |
7.2%
|
37,316,856
|
$152,625,941 | +$20,329,177 | 31 Dec 2025 | |
| Lux Ventures IV, L.P. |
3/4/5
|
Former 10% Owner |
—
class O/S missing
|
13,021,519
|
$137,710,376 | — | 07 Dec 2021 | |
| Mubadala Investment Co PJSC |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
12,985,927
|
$137,333,970 | — | 02 Mar 2023 | |
| STATE STREET CORP |
13F
|
Company |
4.9%
|
25,333,888
|
$103,615,602 | — | 31 Dec 2025 | |
| BAILLIE GIFFORD & CO |
13D/G
13F
|
Company |
4.6%
|
23,774,972
|
$97,239,635 | $0 | 31 Dec 2025 | |
| SOFTBANK GROUP CORP. |
13F
|
Company |
2.6%
|
13,636,515
|
$55,773,346 | — | 31 Dec 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
2.1%
|
10,934,252
|
$44,731,450 | — | 31 Dec 2025 | |
| RA CAPITAL MANAGEMENT, L.P. |
13D/G
|
— |
2%
|
7,725,096
|
$44,187,549 | $0 | 31 Dec 2024 | |
| Zachary Bogue |
3/4/5
|
Director, 10%+ Owner |
—
class O/S missing
|
3,736,341
|
$39,514,048 | — | 03 Jul 2023 | |
| MIC Capital Management UK LLP |
13F
|
Company |
1.9%
|
9,644,032
|
$39,444,095 | — | 31 Dec 2025 | |
| Sumitomo Mitsui Trust Group, Inc. |
13F
|
Company |
1.2%
|
6,221,025
|
$25,443,992 | — | 31 Dec 2025 | |
| Amova Asset Management Americas, Inc. |
13F
|
Company |
1.2%
|
6,221,025
|
$25,381,782 | — | 31 Dec 2025 | |
| Data Collective IV GP, LLC |
13F
|
Company |
1.2%
|
5,941,120
|
$24,299,181 | — | 31 Dec 2025 | |
| NORGES BANK |
13F
|
Company |
1.1%
|
5,739,064
|
$23,472,772 | — | 31 Dec 2025 | |
| MORGAN STANLEY |
13F
|
Company |
1.1%
|
5,657,578
|
$23,139,501 | — | 31 Dec 2025 | |
| Lingotto Investment Management LLP |
13F
|
Company |
0.96%
|
4,931,057
|
$20,168,023 | — | 31 Dec 2025 | |
| Blake Borgeson |
3/4/5
|
Director |
—
mixed-class rows
|
6,273,894
mixed-class rows
|
$19,312,575 | -$3,525,800 | 07 Apr 2026 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP |
13F
|
Company |
0.85%
|
4,396,104
|
$17,980,065 | — | 31 Dec 2025 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
0.82%
|
4,229,999
|
$17,300,696 | — | 31 Dec 2025 | |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC |
13F
|
Company |
0.79%
|
4,075,219
|
$16,667,644 | — | 31 Dec 2025 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.78%
|
3,994,651
|
$16,338,123 | — | 31 Dec 2025 | |
| DCVC Opportunity Fund II GP, LLC |
13F
|
Company |
0.77%
|
3,951,141
|
$16,160,167 | — | 31 Dec 2025 | |
| UBS Group AG |
13F
|
Company |
0.72%
|
3,692,022
|
$15,100,371 | — | 31 Dec 2025 | |
| MIC Capital Partners (Public) Parallel Cayman, LP |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
1,388,889
|
$14,688,335 | — | 01 Nov 2021 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.67%
|
3,439,949
|
$14,069,391 | — | 31 Dec 2025 | |
| FMR LLC |
13F
|
Company |
0.63%
|
3,241,892
|
$13,259,340 | — | 31 Dec 2025 | |
| Dean Y. Li |
3/4/5
|
Director |
—
mixed-class rows
|
3,268,237
mixed-class rows
|
$13,187,001 | — | 01 Apr 2026 | |
| TWO SIGMA INVESTMENTS, LP |
13F
|
Company |
0.6%
|
3,075,123
|
$12,577,253 | — | 31 Dec 2025 | |
| IQ EQ FUND MANAGEMENT (IRELAND) Ltd |
13F
|
Company |
0.47%
|
2,404,118
|
$9,832,843 | — | 31 Dec 2025 | |
| FIRST TRUST ADVISORS LP |
13F
|
Company |
0.44%
|
2,266,691
|
$9,270,766 | — | 31 Dec 2025 | |
| Michael Secora |
3/4/5
|
Chief Financial Officer |
—
mixed-class rows
|
1,836,074
mixed-class rows
|
$9,186,510 | — | 15 Nov 2024 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.43%
|
2,201,442
|
$9,003,898 | — | 31 Dec 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.41%
|
2,112,345
|
$8,639,491 | — | 31 Dec 2025 | |
| Najat Khan |
3/4/5
|
CEO and President, Director |
—
mixed-class rows
|
3,256,029
mixed-class rows
|
$7,566,900 | -$845,425 | 09 Mar 2026 | |
| CAPITAL FUND MANAGEMENT S.A. |
13F
|
Company |
0.35%
|
1,778,976
|
$7,276,011 | — | 31 Dec 2025 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
0.29%
|
1,495,839
|
$6,117,982 | — | 31 Dec 2025 | |
| BARCLAYS PLC |
13F
|
Company |
0.29%
|
1,469,262
|
$6,009,282 | — | 31 Dec 2025 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0.25%
|
1,278,944
|
$5,230,882 | — | 31 Dec 2025 | |
| WELLS FARGO & COMPANY/MN |
13F
|
Company |
0.23%
|
1,160,990
|
$4,748,449 | — | 31 Dec 2025 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.22%
|
1,131,583
|
$4,628,176 | — | 31 Dec 2025 | |
| Nuveen, LLC |
13F
|
Company |
0.21%
|
1,084,925
|
$4,437,344 | — | 31 Dec 2025 | |
| BNP PARIBAS FINANCIAL MARKETS |
13F
|
Company |
0.21%
|
1,084,198
|
$4,434,370 | — | 31 Dec 2025 | |
| Rafferty Asset Management, LLC |
13F
|
Company |
0.19%
|
968,814
|
$3,962,449 | — | 31 Dec 2025 | |
| Comprehensive Financial Management LLC |
13F
|
Company |
0.18%
|
941,895
|
$3,852,351 | — | 31 Dec 2025 | |
| David Hallett |
3/4/5
|
Chief Scientific Officer |
0.21%
|
1,097,151
|
$3,829,056 | — | 17 Feb 2026 | |
| Squarepoint Ops LLC |
13F
|
Company |
0.17%
|
887,004
|
$3,627,846 | — | 31 Dec 2025 | |
| NATIONAL BANK OF CANADA /FI/ |
13F
|
Company |
0.17%
|
875,574
|
$3,581,082 | — | 31 Dec 2025 | |
| Ben R. Taylor |
3/4/5
|
Chief Financial Officer |
—
mixed-class rows
|
1,422,127
mixed-class rows
|
$3,476,130 | -$157,704 | 06 Apr 2026 |
Recent Insider Transactions by Companies or Individuals for RECURSION PHARMACEUTICALS, INC.
Showing up to 300 most recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | Value $ | * Price $ | Shares | Shares Owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Christopher Gibson | RXRX | Class A Common Stock | Sale | -4.23% | $124,000 | $3.10 | -40,000 | 906,556 | 07 Apr 2026 | Direct |
| Christopher Gibson | RXRX | Class A Common Stock | Conversion of derivative security | 4.41% | 40,000 | 946,556 | 07 Apr 2026 | Direct | ||
| Christopher Gibson | RXRX | Class B Common Stock | Conversion of derivative security | -0.89% | -40,000 | 4,443,334 | 07 Apr 2026 | Direct | ||
| Blake Borgeson | RXRX | Class A Common Stock | Sale | -0.48% | $93,000 | $3.10 | -30,000 | 6,229,863 | 07 Apr 2026 | Direct |
| Ben R. Taylor | RXRX | Class A Common Stock | Tax liability | -4.07% | -48,028 | 1,132,290 | 06 Apr 2026 | Direct | ||
| Zavain Dar | RXRX | Class A Common Stock | Award | 3.44% | 4,902 | 147,231 | 01 Apr 2026 | Direct | ||
| Dean Y. Li | RXRX | Class A Common Stock | Award | 0.26% | 3,268 | 1,244,177 | 01 Apr 2026 | Direct | ||
| Christopher Gibson | RXRX | Class A Common Stock | Sale | -4.23% | $130,000 | $3.25 | -40,000 | 906,556 | 23 Mar 2026 | Direct |
| Christopher Gibson | RXRX | Class A Common Stock | Conversion of derivative security | 4.41% | 40,000 | 946,556 | 23 Mar 2026 | Direct | ||
| Christopher Gibson | RXRX | Class B Common Stock | Conversion of derivative security | -0.88% | -40,000 | 4,483,334 | 23 Mar 2026 | Direct | ||
| Ben R. Taylor | RXRX | Class A Common Stock | Sale | -0.67% | $26,971 | $3.39 | -7,956 | 1,180,318 | 17 Mar 2026 | Direct |
| Ben R. Taylor | RXRX | Class A Common Stock | Tax liability | -0.59% | -7,075 | 1,188,274 | 16 Mar 2026 | Direct | ||
| Christopher Gibson | RXRX | Class A Common Stock | Gift | -2.16% | -20,000 | 906,556 | 09 Mar 2026 | Direct | ||
| Christopher Gibson | RXRX | Class A Common Stock | Conversion of derivative security | 2.21% | 20,000 | 926,556 | 09 Mar 2026 | Direct | ||
| Christopher Gibson | RXRX | Class B Common Stock | Conversion of derivative security | -0.44% | -20,000 | 4,523,334 | 09 Mar 2026 | Direct | ||
| Najat Khan | RXRX | Class A Common Stock | Sale | -1.24% | $94,660 | $3.35 | -28,298 | 2,262,085 | 09 Mar 2026 | Direct |
| Blake Borgeson | RXRX | Class A Common Stock | Sale | -2.64% | $588,200 | $3.46 | -170,000 | 6,259,863 | 03 Mar 2026 | Direct |
| Christopher Gibson | RXRX | Class A Common Stock | Sale | -4.23% | $138,400 | $3.46 | -40,000 | 906,556 | 19 Feb 2026 | Direct |
| Christopher Gibson | RXRX | Class A Common Stock | Conversion of derivative security | 4.41% | 40,000 | 946,556 | 19 Feb 2026 | Direct | ||
| Christopher Gibson | RXRX | Class B Common Stock | Conversion of derivative security | -0.87% | -40,000 | 4,543,334 | 19 Feb 2026 | Direct | ||
| Ben R. Taylor | RXRX | Class A Common Stock | Sale | -1.11% | $41,352 | $3.08 | -13,426 | 1,195,349 | 18 Feb 2026 | Direct |
| David Hallett | RXRX | Class A Common Stock | Tax liability | -1.07% | -11,908 | 1,097,151 | 17 Feb 2026 | Direct | ||
| Christopher Gibson | RXRX | Class A Common Stock | Tax liability | -2.92% | -27,265 | 906,556 | 17 Feb 2026 | Direct | ||
| Ben R. Taylor | RXRX | Class A Common Stock | Tax liability | -0.98% | -11,908 | 1,208,775 | 17 Feb 2026 | Direct | ||
| Najat Khan | RXRX | Class A Common Stock | Tax liability | -0.62% | -14,280 | 2,290,383 | 17 Feb 2026 | Direct | ||
| Najat Khan | RXRX | Class A Common Stock | Tax liability | -0.45% | -10,364 | 2,304,663 | 06 Feb 2026 | Direct | ||
| Najat Khan | RXRX | Class A Common Stock | Award | 278.8% | 1,703,892 | 2,315,027 | 06 Feb 2026 | Direct | ||
| Ben R. Taylor | RXRX | Class A Common Stock | Tax liability | -0.93% | -11,400 | 1,220,683 | 06 Feb 2026 | Direct | ||
| Ben R. Taylor | RXRX | Class A Common Stock | Award | 61.8% | 470,533 | 1,232,083 | 06 Feb 2026 | Direct | ||
| David Hallett | RXRX | Class A Common Stock | Tax liability | -1.02% | -11,400 | 1,109,059 | 06 Feb 2026 | Direct | ||
| David Hallett | RXRX | Class A Common Stock | Award | 88.6% | 526,318 | 1,120,459 | 06 Feb 2026 | Direct | ||
| Christopher Gibson | RXRX | Class A Common Stock | Tax liability | -1.1% | -10,364 | 933,821 | 06 Feb 2026 | Direct | ||
| Christopher Gibson | RXRX | Class A Common Stock | Award | 3.32% | 30,346 | 944,185 | 06 Feb 2026 | Direct | ||
| Christopher Gibson | RXRX | Class A Common Stock | Sale | -4.19% | $164,800 | $4.12 | -40,000 | 913,839 | 04 Feb 2026 | Direct |
| Christopher Gibson | RXRX | Class A Common Stock | Conversion of derivative security | 4.38% | 40,000 | 953,839 | 04 Feb 2026 | Direct | ||
| Christopher Gibson | RXRX | Class B Common Stock | Conversion of derivative security | -0.87% | -40,000 | 4,583,334 | 04 Feb 2026 | Direct | ||
| Blake Borgeson | RXRX | Class A Common Stock | Sale | -3.31% | $924,000 | $4.20 | -220,000 | 6,429,863 | 03 Feb 2026 | Direct |
| Christopher Gibson | RXRX | Class A Common Stock | Sale | -4.19% | $178,800 | $4.47 | -40,000 | 913,839 | 20 Jan 2026 | Direct |
| Christopher Gibson | RXRX | Class A Common Stock | Conversion of derivative security | 4.38% | 40,000 | 953,839 | 20 Jan 2026 | Direct | ||
| Christopher Gibson | RXRX | Class B Common Stock | Conversion of derivative security | -0.86% | -40,000 | 4,623,334 | 20 Jan 2026 | Direct | ||
| Blake Borgeson | RXRX | Class A Common Stock | Sale | -3.2% | $959,200 | $4.36 | -220,000 | 6,649,863 | 06 Jan 2026 | Direct |
| Christopher Gibson | RXRX | Class A Common Stock | Gift | -2.14% | -20,000 | 913,839 | 05 Jan 2026 | Direct | ||
| Christopher Gibson | RXRX | Class A Common Stock | Sale | -4.11% | $170,000 | $4.25 | -40,000 | 933,839 | 05 Jan 2026 | Direct |
| Christopher Gibson | RXRX | Class A Common Stock | Conversion of derivative security | 6.57% | 60,000 | 973,839 | 05 Jan 2026 | Direct | ||
| Christopher Gibson | RXRX | Class B Common Stock | Conversion of derivative security | -1.27% | -60,000 | 4,663,334 | 05 Jan 2026 | Direct | ||
| Zavain Dar | RXRX | Class A Common Stock | Award | 2.57% | 3,571 | 142,329 | 02 Jan 2026 | Direct | ||
| Dean Y. Li | RXRX | Class A Common Stock | Award | 0.19% | 2,381 | 1,240,909 | 02 Jan 2026 | Direct | ||
| Ben R. Taylor | RXRX | Class A Common Stock | Sale | -2.73% | $89,381 | $4.18 | -21,383 | 761,550 | 29 Dec 2025 | Direct |
| Najat Khan | RXRX | Class A Common Stock | Sale | -16.9% | $548,592 | $4.41 | -124,403 | 611,135 | 22 Dec 2025 | Direct |
| Christopher Gibson | RXRX | Class A Common Stock | Sale | -4.19% | $180,000 | $4.50 | -40,000 | 913,839 | 19 Dec 2025 | Direct |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.